Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Profile of Diphtheria Antitoxin (DAT) in Indonesia
NCT06053853Phase 4Completed
- Sponsor
- Bio Farma
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of VINDIP in diphtheria, sponsored by Bio Farma. Primary endpoint: Occurrence of serum sickness at 10 days. Started Jan 2023; status: completed.
02
Drugs
VINDIP
03
Conditions
diphtheria
Beyond the preview
Go deeper on NCT06053853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06053853.